Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

160 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Case report: Sotrovimab, remdesivir and nirmatrelvir/ritonavir combination as salvage treatment option in two immunocompromised patients hospitalized for COVID-19.
Baldi F, Dentone C, Mikulska M, Fenoglio D, Mirabella M, Magnè F, Portunato F, Altosole T, Sepulcri C, Giacobbe DR, Uras C, Scavone G, Taramasso L, Orsi A, Cittadini G, Filaci G, Bassetti M. Baldi F, et al. Among authors: fenoglio d. Front Med (Lausanne). 2023 Jan 9;9:1062450. doi: 10.3389/fmed.2022.1062450. eCollection 2022. Front Med (Lausanne). 2023. PMID: 36698815 Free PMC article.
Neutralizing antibodies to Omicron after the fourth SARS-CoV-2 mRNA vaccine dose in immunocompromised patients highlight the need of additional boosters.
Rescigno M, Agrati C, Salvarani C, Giannarelli D, Costantini M, Mantovani A, Massafra R, Zinzani PL, Morrone A, Notari S, Matusali G, Pinter GL, Uccelli A, Ciliberto G, Baldanti F, Locatelli F, Silvestris N, Sinno V, Turola E, Lupo-Stanghellini MT, Apolone G; VAX4FRAIL study Group. Rescigno M, et al. Front Immunol. 2023 Jan 27;14:1104124. doi: 10.3389/fimmu.2023.1104124. eCollection 2023. Front Immunol. 2023. PMID: 36776853 Free PMC article.
Humoral and T-Cell Immune Response After 3 Doses of Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Fragile Patients: The Italian VAX4FRAIL Study.
Corradini P, Agrati C, Apolone G, Mantovani A, Giannarelli D, Marasco V, Bordoni V, Sacchi A, Matusali G, Salvarani C, Zinzani PL, Mantegazza R, Tagliavini F, Lupo-Stanghellini MT, Ciceri F, Damian S, Uccelli A, Fenoglio D, Silvestris N, Baldanti F, Piaggio G, Ciliberto G, Morrone A, Locatelli F, Sinno V, Rescigno M, Costantini M; VAX4FRAIL Study Group. Corradini P, et al. Among authors: fenoglio d. Clin Infect Dis. 2023 Feb 8;76(3):e426-e438. doi: 10.1093/cid/ciac404. Clin Infect Dis. 2023. PMID: 35607769 Free PMC article.
T-cell immunophenotype correlations with cortical thickness and white matter microstructure in bipolar disorder.
Escelsior A, Inuggi A, Sterlini B, Bovio A, Marenco G, Bode J, Favilla L, Tardito S, Altosole T, Pereira da Silva B, Fenoglio D, Filaci G, Amore M, Serafini G. Escelsior A, et al. Among authors: fenoglio d. J Affect Disord. 2024 Mar 1;348:179-190. doi: 10.1016/j.jad.2023.12.054. Epub 2023 Dec 26. J Affect Disord. 2024. PMID: 38154587 Free article.
Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling T-cells, myeloid derived suppressor and NK cells.
Amaro A, Reggiani F, Fenoglio D, Gangemi R, Tosi A, Parodi A, Banelli B, Rigo V, Mastracci L, Grillo F, Cereghetti A, Tastanova A, Ghosh A, Sallustio F, Emionite L, Daga A, Altosole T, Filaci G, Rosato A, Levesque M, Maio M, Pfeffer U, Croce M; EPigenetic Immune-oncology Consortium Airc (EPICA) consortium. Amaro A, et al. Among authors: fenoglio d. J Exp Clin Cancer Res. 2023 Mar 18;42(1):67. doi: 10.1186/s13046-023-02628-x. J Exp Clin Cancer Res. 2023. PMID: 36934257 Free PMC article.
Trojan-horse silk fibroin nanocarriers loaded with a re-call antigen to redirect immunity against cancer.
Bari E, Ferrera F, Altosole T, Perteghella S, Mauri P, Rossi R, Passignani G, Mastracci L, Galati M, Astone GI, Mastrogiacomo M, Castagnola P, Fenoglio D, Di Silvestre D, Torre ML, Filaci G. Bari E, et al. Among authors: fenoglio d. J Immunother Cancer. 2023 Jan;11(1):e005916. doi: 10.1136/jitc-2022-005916. J Immunother Cancer. 2023. PMID: 36697251 Free PMC article.
160 results